BioMarin gets CHMP green light for Vimizim
This article was originally published in Scrip
Executive Summary
Hot on the heels of FDA approval, experts on the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of BioMarin's enzyme replacement therapy Vimizim (elosulfase alfa) for the treatment of the lysosomal storage disorder Morquio A syndrome, also called mucopolysaccharidosis type IVA (MPS IVA). Earlier this month, the FDA approved Vimizim for the same indication (scripintelligence.com, 15 February 2014).